Published in:
01-11-2018 | Correspondence
cIMPACT-NOW update 3: recommended diagnostic criteria for “Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV”
Authors:
Daniel J. Brat, Kenneth Aldape, Howard Colman, Eric C. Holland, David N. Louis, Robert B. Jenkins, B. K. Kleinschmidt-DeMasters, Arie Perry, Guido Reifenberger, Roger Stupp, Andreas von Deimling, Michael Weller
Published in:
Acta Neuropathologica
|
Issue 5/2018
Login to get access
Excerpt
The World Health Organization (WHO) central nervous system tumor classification represents the primary source of updates on diagnostic classes, grades and criteria [
17]. However, recent and ongoing advances in our understanding of brain tumor molecular pathogenesis warrant more rapid integration of this information into clinical practice between WHO updates. To accomplish this, cIMPACT-NOW (the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy) was established in 2016 [
15,
16]. Since then, cIMPACT-NOW has convened three separate working committees to address classification and grading questions and challenges. Working Committee 1 focused on a concern that the classification and grading of Isocitrate Dehydrogenase (IDH)-wildtype diffuse astrocytic gliomas do not reflect our current understanding of the molecular pathogenesis and clinical outcomes associated with these tumors. …